How little is too much? p53 inactivation: From laboratory cutoff to biological basis of chemotherapy resistance

Leukemia

Volumn 22, Issue 12, 2008, Pages 2257-2258

  Zenz, T ^a   Habe S ^a   Denzel, T ^a   Winkler, D ^a   Dohner H ^a   Stilgenbauer, S ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN P53; RITUXIMAB;

ADULT; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; HETEROZYGOSITY; HUMAN; LETTER; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT INDICATION; WILD TYPE;

EID: 57849158643     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.114     Document Type: Letter

References (8)

1. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al., UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group: NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007; 370: 230-239.
2. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
3. Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477-484.
4. Trbusek M, Malcikova J, Smardova J, Kuhrova V, Mentzlova D, Francova H et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 2006; 20: 1159-1161.
5. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441-1445.
6. Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005; 90: 1435-1436.
7. Stilgenbauer S, Döhner H. Alemtuzumab-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453.
8. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute - Working Group (NCI-WG) 1996 guidelines. Blood 2008; published online 23 January 2008, doi:10.1182/blood-2007-06-093906.